ArticlePediatric research2026
Point-of-care serum bilirubin as an efficient and comparable alternative to hospital based testing.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeonatal hyperbilirubinemia is common, with significant elevations resulting in long-term neurological impairments or death, if untreated. Hospital-based analyzers are the gold standard for measuring total serum bilirubin (TSB), but are expensive, technically demanding, and often unavailable in lower resource settings. The purpose of this study was to compare TSB between the Bilistick System 2.0 point-of-care (Bilistick POC) and hospital-based analyzer (Hospital) under real-world conditions.
methodsThis prospective diagnostic study was conducted in a Southwest Ohio community-based healthcare system by 6 study investigators, across 4 test sites, and included 80 newborns (<2 weeks old, 31-42 weeks' gestation) scheduled for TSB testing. Newborn blood TSB was tested with Bilistick POC and Hospital analyzers, plus 25 bilirubin spiked adult samples to extend the TSB range.
resultsBilistick POC and Hospital TSB showed high correlation (R² = 0.99, p < 0.001) across devices, investigators, and locations. Bland-Altman analysis demonstrated minimal bias (mean ratio = 1.005) with 95% limits (0.8426-1.167), over TSB of 2.3-29.5 mg/dL. No significant inter-investigator variation was detected (p = 0.107) and hemolysis was minimal (7.5%).
conclusionThese findings support Bilistick POC as an easily utilized, consistent, and portable testing device to measure TSB compared to a hospital-based analyzer. IMPACT: Point-of-care testing for total serum bilirubin with the Bilistick 2.0 point-of-care system (Bilistick POC) is a more affordable, faster, reliable, consistent, easy-to-use, and more efficient method compared to expensive hospital laboratory equipment. Resource-limited settings may benefit from POC TSB testing where advanced laboratory infrastructure is limited. The Bilistick POC testing device is comparable to hospital-based testing analyzers.
Indexed as
Identifiers
41436633What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.